| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
None. DOPC is an excipient that interacts with other lipids and cholesterol to form bilayer membranes. It does not have a specific protein or receptor target. |
|---|---|
| ln Vitro |
DOPC forms stable, fluid bilayer membranes capable of encapsulating both hydrophilic and lipophilic drugs. It is commonly used in liposomes for drug delivery (e.g., doxorubicin). DOPC-based liposomes have low permeability to encapsulated small molecules. DOPC enhances LNP stability and encapsulation efficiency when combined with ionizable cationic lipids for nucleic acid delivery.
|
| ln Vivo |
In vivo, DOPC-containing liposomes and LNPs demonstrate extended circulation time due to the fluid bilayer (unsaturated chains). They are biocompatible and biodegradable, with no intrinsic biological activity. DOPC-based formulations deliver chemotherapeutic agents to tumors via the enhanced permeability and retention (EPR) effect and deliver nucleic acids to the liver when formulated in LNPs.
|
| Enzyme Assay |
DOPC is typically dissolved in chloroform or ethanol and mixed with other lipids at defined molar ratios (e.g., 20-60 mol%). For liposome preparation, the lipid mixture is dried under nitrogen to form a thin film, hydrated with aqueous buffer, and extruded through polycarbonate membranes (100-200 nm pores) to achieve uniform unilamellar vesicles (LUVs). For LNPs, DOPC is combined with ionizable lipids, cholesterol, and PEG-lipids and processed via microfluidic mixing or ethanol injection methods. Particle size, zeta potential, and encapsulation efficiency are characterized by DLS and fluorescence assays.
|
| Cell Assay |
For cell studies, DOPC liposomes or LNPs are diluted in serum-free or complete media. Cells (e.g., HeLa, HEK293) are incubated with formulations (0.1-5 mg/mL total lipid) for 2-24 h. Cellular uptake is assessed by fluorescently labeled lipids or encapsulated dyes via flow cytometry or confocal microscopy. Cytotoxicity is evaluated using MTT assays, with DOPC typically showing no significant toxicity at tested concentrations.
|
| Animal Protocol |
In animal studies, DOPC-based formulations are administered intravenously (tail vein), intraperitoneally, or intratumorally to mice or rats at doses of 5-50 mg/kg lipid. Biodistribution is assessed by fluorescent imaging or by quantifying encapsulated drug content in tissues (e.g., liver, spleen, tumor) via HPLC or LC-MS/MS. For therapeutic efficacy, tumor growth inhibition or target gene knockdown is evaluated.
|
| ADME/Pharmacokinetics |
DOPC itself does not exhibit significant pharmacological PK properties as an excipient. However, DOPC-containing LNPs have a plasma half-life of approximately 2-6 h following i.v. administration. DOPC is metabolized via phospholipase hydrolysis of the ester bonds, releasing free fatty acids (oleic acid) and choline, which enter normal metabolic pathways. Minimal intact DOPC is detected in the circulation beyond 24 h.
|
| Toxicity/Toxicokinetics |
DOPC is widely recognized as safe (GRAS) by regulatory authorities. Intravenous administration of DOPC liposomes is generally well-tolerated with minimal toxicity. High doses (>500 mg/kg) may cause transient lipemia or mild splenomegaly. DOPC is non-immunogenic and biodegradable, making it an ideal excipient for pharmaceutical formulations.
|
| Additional Infomation |
1,2-Dioleoyl-sn-glycero-3-phosphocholine is a phosphatidylcholine 36:2, in which the phosphatidyl acyl groups at positions 1 and 2 are both oleoyl groups. It is a 1-acyl-2-oleoyl-sn-glycero-3-phosphocholine betaine, and also a 1,2-octadecenoyl-sn-glycero-3-phosphocholine. Functionally, it is associated with oleic acid. It is the conjugate base of 1,2-dioleoyl-sn-glycero-3-phosphocholine (1+).
1,2-Dioleoyl-sn-glycero-3-phosphocholine has been reported and data are available. PC (18:1(9Z)/18:1(9Z)) is a metabolite found or produced in Saccharomyces cerevisiae. DOPC (CAS 4235-95-4, C44H₈4NO₈P, MW 786.1) has >98% purity and is supplied as a white to off-white powder or waxy solid. Storage at -20degC under nitrogen is recommended to prevent oxidation of unsaturated oleoyl chains. DOPC is used in FDA-approved liposomal drug products (e.g., liposomal doxorubicin) and in numerous preclinical LNP formulations for mRNA and siRNA delivery. It is not intended for direct therapeutic use but serves as an excipient. |
| Molecular Formula |
C44H84NO8P
|
|---|---|
| Molecular Weight |
786.11
|
| Exact Mass |
785.593
|
| CAS # |
4235-95-4
|
| Related CAS # |
1,2-Dioleoyl-sn-glycero-3-phosphocholine-d9
|
| PubChem CID |
10350317
|
| Appearance |
Colorless to off-white <-21 °C solid powder,>-21 °C liquid
|
| LogP |
11.97
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
42
|
| Heavy Atom Count |
54
|
| Complexity |
972
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
P(=O)([O-])(OC([H])([H])C([H])(C([H])([H])OC(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)OC(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)OC([H])([H])C([H])([H])[N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
SNKAWJBJQDLSFF-NVKMUCNASA-N
|
| InChi Code |
InChI=1S/C44H84NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h20-23,42H,6-19,24-41H2,1-5H3/b22-20-,23-21-/t42-/m1/s1
|
| Chemical Name |
[(2R)-2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (127.21 mM)
Ethanol: 50 mg/mL (63.60 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2721 mL | 6.3604 mL | 12.7209 mL | |
| 5 mM | 0.2544 mL | 1.2721 mL | 2.5442 mL | |
| 10 mM | 0.1272 mL | 0.6360 mL | 1.2721 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
